|Mr. Pablo Gerardo Legorreta||Founder, Chairman & CEO||55.67M||N/A||1964|
|Mr. Terrance P. Coyne||Exec. VP & CFO||3.4M||N/A||N/A|
|Dr. James Folmar Reddoch Ph.D.||Exec. VP, Chief Scientific Officer and Co-Head of Research & Investments||3.4M||N/A||1970|
|Mr. George Wingate Lloyd||Exec. VP of Investments & Gen. Counsel||3.4M||N/A||1960|
|Mr. Christopher Hite||Vice Chairman & Exec. VP||3.8M||N/A||1968|
|Dr. Marshall Urist M.D., Ph.D.||Exec. VP and Co-Head of Research & Investments||N/A||N/A||N/A|
|Mr. Sandy Balkin Ph.D.||Sr. VP of Strategy & Analytics||N/A||N/A||N/A|
|Ms. Sarah Cata||VP & Treasurer||N/A||N/A||N/A|
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 7; Compensation: 7.